Eric Vangrevelinghe
Novartis (Switzerland)(CH)Novartis (China)(CN)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Myeloproliferative Neoplasms: Diagnosis and Treatment, Protein Kinase Regulation and GTPase Signaling, Computational Drug Discovery Methods, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking(2003)215 cited
- → A Small-Molecule Dengue Virus Entry Inhibitor(2009)206 cited
- → Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition(2012)162 cited
- → Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent(2012)127 cited
- → Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia(2015)121 cited
- → Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805(2010)119 cited
- → Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family